MTN 038

Principal Investigator(s):
Objective:A Phase 1, Randomized, Pharmacokinetic and Safety Study of a 90 Day Intravaginal Ring Containing Tenofovir   Last updated May 3, 2021
Prevention Option(s):Microbicides
Study Design:Randomized
Arms and Assigned Interventions
DescriptionExperimental: Tenofovir (TFV) Intravaginal Ring (IVR) The TFV IVR will be inserted during the enrollment visit (Day 0) and used continuously for approximately 91 days. Drug: Tenofovir (TFV) IVR Contains 1.4 g TFV
Mode of DeliveryRing
Official Code: NCT03670355
Trial Sponsors: NIAID (DAIDS-ES: 38460)
Start Date
End Date
December 7, 2018
September 25, 2019
Age range: 18 Years ↔ 45 Years
Population:Cisgender Women